A prostate stent is a small, tube-shaped device inserted into the urethra where it passes through the prostate gland, physically holding the channel open so urine can flow freely. It works like a scaffold inside a collapsing tunnel: when an enlarged prostate squeezes the urethra shut, the stent pushes back against the tissue and restores a clear passage from the bladder to the outside. Prostate stents have been around since the 1980s, though the designs have changed considerably, and they occupy a specific niche in urology rather than serving as a universal fix for prostate problems.
Why the Urethra Gets Blocked in the First Place
The prostate sits just below the bladder and wraps around the urethra like a doughnut. In benign prostatic hyperplasia (BPH), the gland’s tissue grows inward, gradually narrowing the urethral channel. BPH involves an overgrowth of connective tissue, smooth muscle, and glandular cells within the prostate, and the expanding tissue can compress the urethra enough to create a real blockage.1PubMed Central. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction The result is what urologists call bladder outlet obstruction: you feel the urge to urinate, but the stream is weak, slow to start, or interrupted. Over time, the bladder has to work harder to push urine past the blockage, and in severe cases urine backs up entirely, a condition called urinary retention.
Most men with BPH manage fine with medications or, when those stop working, surgery to remove or shrink the excess prostate tissue. A prostate stent enters the conversation when those standard options aren’t feasible.
Who Actually Gets a Prostate Stent
Prostate stents are not a first-line treatment. They exist primarily for men who can’t safely undergo surgery or general anesthesia. Roughly 10% to 15% of men with BPH fall into this category because of serious coexisting health problems like advanced heart disease, lung conditions, or extreme frailty.2PubMed. Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients For these patients, the alternative is often a long-term indwelling catheter, which comes with its own set of problems. A stent can offer a way to restore urination without the risks of an operating room.
Stents are also used in men with urethral obstruction caused by prostate cancer. A study of self-expandable metallic stents in cancer patients found meaningful improvements in urine flow rates and symptom scores, with stents maintained for about six months. The patients in that study had advanced disease, poor overall health, and were unsuitable for general anesthesia, making the stent a palliative tool to preserve quality of life in their remaining time.3PubMed. Efficacy and tolerability of metallic stent in patients with malignant prostatic obstruction secondary to prostatic cancer
Beyond these long-term placements, temporary stents sometimes serve as a bridge. A man in acute urinary retention might get a stent placed for a few weeks or months while waiting for a surgical slot, recovering from another procedure, or stabilizing a separate medical condition.
How the Stent Gets Placed
Placement is a minimally invasive procedure, often done in an outpatient or office setting. The patient lies on their back, and the urologist uses ultrasound to confirm the size of the prostate. After applying local anesthesia (typically a numbing gel in the urethra) or light sedation, a flexible cystoscope is threaded through the urethra into the bladder. The scope lets the urologist see the prostatic urethra directly and measure the distance from the bladder neck to a key anatomical landmark called the verumontanum. That measurement determines which stent size to use.4Prostate Cancer and Prostatic Diseases. Feasibility and safety study of the Flostent™ system (RAPID-I)
Once the right size is selected, the stent is loaded onto a delivery tool and pushed through the cystoscope’s working channel. The urologist positions it within the prostatic urethra, releases it, and then uses the scope to confirm it’s sitting in the right place and the channel is open. The whole process is quick, with many newer stent systems designed so that about 90% of insertions are rated as easy by the treating physician.5PubMed Central. Outcomes of the novel EXIME prostate stent: initial experience in a South African setting Most patients tolerate it with only minimal discomfort.
The Different Types of Prostate Stents
Not all prostate stents are the same. The major categories differ in how long they stay in the body and what happens to them over time.
- Permanent stents: These are designed to stay in the body indefinitely. The UroLume, one of the earliest models developed in the early 1990s, is a mesh-like device that becomes covered by the urethra’s own lining over time, a process called epithelialization. Once the tissue grows over the stent, it essentially becomes part of the urethral wall. The upside is that it doesn’t need to be removed; the downside is that if problems arise, removal can be difficult.
- Temporary metallic stents: The Memokath is the best-known example. Made from a nickel-titanium alloy, it expands when exposed to warm water and contracts when cooled, making it relatively straightforward to insert and retrieve. It’s designed to resist tissue ingrowth, so the urethral lining doesn’t cover it. That makes removal easier but means the body treats it as a foreign object for as long as it’s in place.
- Biodegradable stents: These dissolve on their own over weeks to months, eliminating the need for a removal procedure. Materials like poly-L-lactic acid and poly-lactic-co-glycolic acid (PLGA) have been used. In animal studies, braided PLGA stents degraded smoothly in one to two months.6PubMed. A new biodegradable braided self-expandable PLGA prostatic stent: an experimental study in the rabbit In human use, a related copolymer stent took two to two and a half months to degrade, was still intact at two months, had broken into fragments by four months, and was completely gone by six months.7PubMed. Interstitial laser coagulation and biodegradable self-expandable, self-reinforced poly-L-lactic and poly-L-glycolic copolymer spiral stent in the treatment of benign prostatic enlargement
The earlier generations of all these types had fairly high complication rates, including pain, incontinence, infections, migration, and blockage.8PubMed Central. Prostatic stents: a narrative review of current evidence Newer designs have been engineered specifically to address those problems, and a handful of next-generation stents are now in clinical trials or early commercial use.
How Well Do They Actually Work
Across published studies, prostate stents consistently improve the key measurements urologists care about. A systematic review found that, on average, stents improved symptom scores by about 10 points on the International Prostate Symptom Score, boosted peak urine flow by roughly 7 mL per second, and reduced the amount of urine left in the bladder after voiding by about 147 mL.9Prostate Cancer and Prostatic Diseases. Prostatic stents: a systematic review and analysis of functional outcomes and complication rate Those numbers translate to real, noticeable relief: a stronger stream, less frequent trips to the bathroom, and less of that frustrating feeling of incomplete emptying.
A randomized trial of a newer stent design (the ProVee) compared to a sham procedure provides some of the strongest evidence to date. The stent group showed more than 25% greater improvement in symptom scores at three months compared to sham, and symptom improvement from baseline exceeded 30% at twelve months.10PubMed Central. 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia The sham control is important here: urological procedures often have a strong placebo effect, so knowing the stent outperformed a fake procedure at three months, and sustained benefit at a year, is meaningful evidence that the device itself is doing something real.
That said, durability varies widely depending on the stent type and the patient. Reviews of minimally invasive treatments for BPH note that benefit duration ranges from about one to five years depending on the device.11PubMed Central. State-of-the-art in minimally invasive treatments for benign prostatic obstruction Older temporary metallic stents like the Memokath have not been shown to offer durable long-term relief, and some reviewers have concluded they cannot yet be broadly recommended.12PubMed. Beyond medications: office-based procedures for benign prostatic obstruction The newer devices are more promising, but the evidence base is still building.
Complications and What Can Go Wrong
No implanted device is free of problems, and prostate stents have a well-documented history of complications, particularly with older designs. The main issues fall into a few categories.
Migration is when the stent shifts from its intended position, either sliding deeper toward the bladder or slipping outward. This can cause the blockage to return or create new symptoms. Encrustation, where mineral deposits build up on the stent surface, is another concern, especially with longer-dwelling devices. And with permanent stents that rely on tissue ingrowth, the healing process can overshoot: overgrown tissue can narrow or even re-block the channel, a process related to poor epithelialization.13PubMed. Epithelialization of permanent stents The North American trial of the UroLume documented migration, encrustation, tissue overgrowth, pain, and irritative voiding symptoms, though overall complication rates were described as minimal and few stents required removal.14PubMed. Uncommon complications of permanent stents
Some newer designs have fared better. Studies of the Memokath in elderly patients reported no serious complications after insertion.15PubMed. Efficacy of a thermoexpandable metallic prostate stent (Memokath) in elderly patients with urethral obstruction requiring long-term management with urethral Foley catheters The Allium stent, another newer design, showed no migration or obstruction in its initial human report.16PubMed. Allium™ TPS–A New Prostatic Stent for the Treatment of Patients with Benign Prostatic Obstruction: The First Report These are encouraging, but the sample sizes are small and follow-up periods short. The honest assessment is that complications have decreased with each generation of stent design, but they haven’t been eliminated.
Stents Versus Long-Term Catheters
For many of the frail, high-risk patients who end up with prostate stents, the realistic alternative is an indwelling urethral catheter, a tube left in the bladder that drains urine continuously into a bag. Catheters work, but they carry a significant infection risk. Catheter-associated urinary tract infections are one of the most common healthcare-acquired infections, with estimated rates of 3.1 to 7.5 infections per 1,000 catheter days in the United States.
By comparison, a study of temporary prostatic stents in a large urology practice found a urinary tract infection rate of 0.93 per 1,000 stent days, roughly a quarter to a seventh of the catheter infection rate.17Canadian Journal of Urology. Treating male retention patients with temporary prostatic stent in a large urology group practice That difference is substantial over months of use. Beyond infection, catheters can cause urethral irritation, bladder spasms, and accidental dislodgement. They also tether the patient to a drainage bag, which limits mobility and daily activities. A well-functioning stent allows a man to urinate normally, without any external device.
Data from the EXIME prostate stent showed that markers of bacterial colonization dropped dramatically during the stenting period, with nitrite positivity on urine dipstick falling from 26% before insertion to 0% at removal.5PubMed Central. Outcomes of the novel EXIME prostate stent: initial experience in a South African setting If used more broadly, stents could help reduce the burden of catheter-related infections and their associated costs and hospital stays.18The Canadian Journal of Urology. Treating male retention patients with temporary prostatic stent in a large urology group practice
What Happens to Sexual Function
This is a question most men think about but don’t always ask. Prostate surgery carries well-known risks to erections and ejaculation, and men considering a stent reasonably want to know whether a device sitting inside the prostate will affect sex.
The evidence is mixed but generally reassuring on erectile function. A study of the Horizon temporary stent found no change in overall sexual function scores or erectile function at one and three months after placement. Where the stent did cause problems was with orgasm and ejaculation: some men reported painful ejaculation (rising from 1% at baseline to 4% at one month), and retrograde ejaculation (where semen goes backward into the bladder instead of out) also increased, reaching about 7% at three months. Intercourse satisfaction initially dipped but recovered and actually improved beyond baseline by three months.19Central European Journal of Urology. The effect of a temporary prostatic stent on sexual function
A more recent study of the EXIME stent reported an 88% resumption rate of sexual activity among men who were sexually active before the procedure.5PubMed Central. Outcomes of the novel EXIME prostate stent: initial experience in a South African setting Across the broader category of minimally invasive BPH treatments, rates of ejaculatory and erectile problems remain low.11PubMed Central. State-of-the-art in minimally invasive treatments for benign prostatic obstruction So the short answer is: stents are generally kinder to sexual function than traditional surgery, though some men will notice changes in how ejaculation feels or works.
Removing a Temporary Stent
If a non-permanent stent needs to come out, the process is simpler than you might expect. A review of thermo-expandable stent removals across three medical centers found that the procedure took an average of 11 minutes. Nearly half of patients had the stent removed with only topical anesthesia or no anesthesia at all, and among those patients, only 9% reported moderate discomfort or worse. About a third went home the same day without needing observation. The urologist rated the removal as easy or fairly easy in 90% of cases.20PubMed. Ease of removal of thermo-expandable prostate stents
The average time stents had been in place before removal was about 13 months, and the reasons for taking them out varied: recurring urinary symptoms, stent migration, pain, repeated infections, or bladder muscle failure. This is worth knowing because it sets realistic expectations. A temporary stent is not always a set-and-forget solution. Some proportion of men will need the stent removed and a different approach tried.
Newer Devices and Where the Field Is Headed
The stent landscape is evolving faster now than it has in decades. Earlier devices had a reputation for high complication rates that made many urologists reluctant to use them. The newer generation addresses specific failure modes of the old designs. Some use coatings or geometric features to resist encrustation and tissue ingrowth. Others are shaped to anchor themselves more securely, reducing migration. The ProVee stent’s sham-controlled trial marks a significant step because it applies the gold standard of evidence (randomized, blinded, with a control group) to a device category that has historically been supported only by single-arm observational studies.10PubMed Central. 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia
Biodegradable stents remain an appealing concept because they eliminate the removal question entirely. The challenge has been controlling the degradation rate precisely: dissolve too fast and the benefit is too brief, dissolve too slowly and fragment remnants can cause irritation. Research continues on tuning polymer formulations to hit the right window.
The broader trend in BPH treatment is toward procedures that can be done in a doctor’s office under local anesthesia, with minimal recovery time and low impact on sexual function. Prostate stents fit squarely in that direction. They won’t replace surgery for men who are healthy enough for it and have large prostates, but for the growing population of older men with multiple health problems, a 15-minute office procedure that restores normal urination for months to years is a compelling proposition. The evidence isn’t yet strong enough for stents to be routine, but the trajectory of the research, particularly with sham-controlled data now entering the literature, suggests they’re moving from a niche last resort toward a more mainstream option for the right patient.